Librela and a similar treatment for cats and dogs are an important franchise for maker Zoetis, but “now they are at the center of a medical mystery” as some pet owners blame the drugs for sickening their animals, according to a report by The Wall Street Journal’s Jennifer Calfas. Health regulators in the U.S. and Europe are conducting reviews, but Zoetis says the medicines are safe, with reports of side effects representing well less than 1% of the more than 18 million shots of both drugs combined administered to date in the U.S. and abroad, the report noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTS:
- ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy?
- Zoetis price target lowered to $195 from $215 at Stifel
- Zoetis Expands Board with New Director, Emphasizes Governance
- 5 Best Healthcare Stocks to Buy in March 2024, According to Analysts
- Discounted Zoetis price offers buing opportunity, says Argus